<DOC>
	<DOCNO>NCT00000772</DOCNO>
	<brief_summary>To evaluate safety tolerance concurrent administration standard-dose didanosine ( ddI ) low-dose ribavirin HIV-positive patient . To determine pharmacokinetic interaction concurrent administration ddI ribavirin correlate pharmacokinetic parameter toxicity . To investigate antiviral activity combine regimen . Combination ddI/ribavirin therapy , safe effective , offer alternative combination antiretroviral regimen patient unable tolerate regimen contain zidovudine ( AZT ) .</brief_summary>
	<brief_title>A Phase I Open-Label Study Safety , Tolerance , Pharmacokinetic Interactions Combination Didanosine Ribavirin HIV-Positive Individuals</brief_title>
	<detailed_description>Combination ddI/ribavirin therapy , safe effective , offer alternative combination antiretroviral regimen patient unable tolerate regimen contain zidovudine ( AZT ) . Patients receive ddI alone 4 week , follow 8 week combination ddI/ribavirin . Patients complete first 12 week without major toxicity may receive additional 12 week combination therapy optional basis . Patients follow 60 day last treatment visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Stable maintenance prophylaxis therapy opportunistic infection , therapy administer least 30 day prior study entry . Isoniazid chemoprophylaxis Mycobacterium tuberculosis . Fluconazole mucosal candidiasis cryptococcosis . Acyclovir ( 1.0 g/day ) . Dapsone . Ketoconazole . Quinolones . Tetracycline . Vitamins herbal therapy . Antibiotics clinically indicate . Systemic corticosteroid &lt; 21 day acute problem . Regularly prescribed medication . Patients must : HIV positivity ELISA confirm Western blot . CD4 count &lt; 500 cells/mm3 within 30 day prior study entry . No active opportunistic infection require treatment ( patient stable maintenance prophylaxis therapy opportunistic infection least 30 day permit ) . NOTE : Enrollment woman encourage . Prior Medication : Allowed : Prior stable maintenance prophylaxis therapy opportunistic infection , administer least 30 day prior study entry . Exclusion Criteria Concurrent Medication : Excluded : Concurrent rifampin rifabutin . Other antiHIV drug investigational agent . Biological response modifier . Ganciclovir foscarnet . Systemic cytotoxic chemotherapy . Concurrent Treatment : Excluded : Concurrent radiation therapy limit localized therapy skin . Patients follow prior condition exclude : History peripheral neuropathy . History pancreatitis active liver disease . Prior Medication : Excluded : Prior ddI . Ribavirin within 60 day prior study entry . AZT ddC within 2 week prior study entry . Prior Treatment : Excluded : Transfusion within 2 week prior study entry . Active alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>